<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ870703-0056 </DOCNO><HL> ICN PharmaceuticalsPosts 2nd-Period LossTotaling 41.7 Million</HL><DD> 07/03/87</DD><SO> WALL STREET JOURNAL (J)</SO><IN> ICN VIRA SPIPEARNINGS (ERN) </IN><DATELINE> COSTA MESA, Calif.  </DATELINE><TEXT>   ICN Pharmaceuticals Inc. reported a net loss for its second quarter, ended May 31, of $1.7 million compared with net income of $1.6 million, or eight cents a share, a year earlier.    The most recent period's results included an extraordinary gain of $1.5 million compared with an extraordinary loss in the year-ago quarter of $60,000. The company identified one gain in the recent period of $1.4 million from the buyback of debt securities.    Sales in the second quarter were $29.3 million, up 29% from the year-ago $22.7 million.    Company officials weren't available for comment, and the pharmaceutical and biochemical company didn't provide an explanation of the results. The Food and Drug Administration recently declined to approve expanded use of the company's drug, Ribavirin, for the treatment of patients with a condition related to acquired immune deficiency syndrome, or AIDS.    For its first half, ICN reported net income of $5 million, or 24 cents a share, up 39% from $3.6 million, or 22 cents a share, the year before. The most recent results included an extraordinary gain of $5.2 million, compared with an extraordinary gain of $915,000 in the year-ago period.    Sales in the six months were $51.7 million, up 8% from $47.9 million.    ICN shares closed yesterday at $11.75, unchanged, in New York Stock Exchange composite trading.    Separately, Viratek Inc., in which ICN holds a 56% stake, reported a second-quarter net loss of $2.7 million, compared with a loss of $567,000 a year earlier. Revenue was $202 million, down sharply from $647 million last year. The company was hurt by increased research and development costs, among other things.    SPI Pharmaceuticals Inc., in which ICN holds a 90% stake, posted second-quarter net income of $2.6 million, or 25 cents a share, compared with net of $2.2 million, or 22 cents a share, in the year-ago quarter. Sales were $19 million, up 56% from $12.2 million last year. SPI Pharmaceuticals makes, distributes and markets pharmaceutical products and related services. </TEXT></DOC>